TOP NEWS

Ligand Inks Licensing Deal With Venture Capital Investor

San Diego-based Ligand Pharmaceuticals said on Friday that it has entered into a deal with venture capital investor venBio Partners, which will allow venBio's portfolio companies to enter into a pre-agreed worldwide OmniAb platform license agreement. Financial details of those agreements were not announced, however, Ligand said i will be eligible to receive access payments, development and regulatory milestone payments, and tiered royalties for each product incorporating an OmniAb antibody. The two said the deal will result in venBio incubating a series of new companies based on OmniAb's technology. OmbiAb is developing technology used for producing mono- and bispecific human therapeutic antibodies.